嚴兆基

恆 指 及 股 票 推 介

2017-04-05

 

一週回顧

0327

0328

0329

0330

0331

/

星期一

星期二

星期三

星期四

星期五

港股成交金額 (億港元)

890

694

772

731

736

 

恒生指數

24193

24345

24392

24301

24111

- 247

國企指數

10362

10425

10437

10355

10273

- 204

日經平均指數

18985

19202

19217

19063

18909

- 353

杜瓊斯工業指數

20550

20701

20659

20728

20663

+ 67

                                                                                                                                        

股份推介:  三生製藥(1530)

建議 : ($9.50 )
止蝕位 : $9.00  目標價:$11.00

 

理由: 三生製藥業績理想

三生製藥(1530)截至去年12月底止全年錄得純利7.13億元人民幣,按年增長35.4%,期內營業額27.97億元,按年升67.19%,業績理想。公司旗下益賽普和特比澳獲納入全國醫保目錄,預計今年銷售加速增長。公司透過收購拓展糖尿病藥物領域,帶來新的增長動力。筆者建議投資者於9.5元買入三生製藥(1530),目標價11元,止蝕定於9元。

 
 (筆者嚴兆基為證監會持牌人士, 並沒持有上述股份權益)

 

 風險聲明:-

本文提供之內容僅供參考 並不構成要約、招攬或邀請、宣傳、誘使、任何不論種類或形式之申述或立任何交易的任何建議或推薦。若干投資產品並非適合每位投資者, 投資者須因應本身之投資經驗、投資目標、財政資源及其他相關條件, 小心衡量本身是可適合參予有關買賣。投資產品的價格及其收益可升亦可跌, 在若干情況下投資者可能會損失全部資本。

                                                                                

(The above displayed are just writers’ own opinions and for readers’ reference only. Financial markets are volatile and please be careful of the risks.)NOTICE

Investment involves risk. It is as likely that losses will be incurred rather than profits made as a result of buying and selling investment and financial products. Before investment, you should be aware of all the risks involved and carefully consider your investment objectives, trading experience, and level of risk acceptance. If you have any question, please seek advice from an independent professional advisor.

  • WeChat
  • QQ